MA71257A - Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant - Google Patents

Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant

Info

Publication number
MA71257A
MA71257A MA71257A MA71257A MA71257A MA 71257 A MA71257 A MA 71257A MA 71257 A MA71257 A MA 71257A MA 71257 A MA71257 A MA 71257A MA 71257 A MA71257 A MA 71257A
Authority
MA
Morocco
Prior art keywords
itga2
antibody
drug conjugates
antibodies targeting
targeting
Prior art date
Application number
MA71257A
Other languages
English (en)
Inventor
Wei Li
Catherine C. Wong
Pei Han
Original Assignee
Foreseen Technology (Beijing) Co., Ltd.
Foreseen Biotechnology (Shanghai) Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foreseen Technology (Beijing) Co., Ltd., Foreseen Biotechnology (Shanghai) Co., Ltd. filed Critical Foreseen Technology (Beijing) Co., Ltd.
Publication of MA71257A publication Critical patent/MA71257A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71257A 2022-06-27 2023-06-02 Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant MA71257A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210743539 2022-06-27
EP23829854.1A EP4545563A1 (fr) 2022-06-27 2023-06-02 Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant
PCT/CN2023/098076 WO2024001669A1 (fr) 2022-06-27 2023-06-02 Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant

Publications (1)

Publication Number Publication Date
MA71257A true MA71257A (fr) 2025-04-30

Family

ID=89382806

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71257A MA71257A (fr) 2022-06-27 2023-06-02 Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant

Country Status (13)

Country Link
EP (1) EP4545563A1 (fr)
JP (1) JP2025524306A (fr)
KR (1) KR20250042144A (fr)
CN (1) CN119343378A (fr)
AU (1) AU2023301621A1 (fr)
CA (1) CA3259463A1 (fr)
CL (1) CL2024004023A1 (fr)
CO (1) CO2025000762A2 (fr)
IL (1) IL317725A (fr)
JO (1) JOP20240284A1 (fr)
MA (1) MA71257A (fr)
MX (1) MX2024016011A (fr)
WO (1) WO2024001669A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025208742A1 (en) * 2024-01-19 2026-07-23 Foreseen Technology (Beijing) Co., Ltd. An anti_itga2 antibody drug conjugate
CN119241709B (zh) * 2024-10-24 2025-04-01 兰州大学 Itga2单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
KR101281501B1 (ko) * 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
PL1948798T3 (pl) * 2005-11-18 2015-12-31 Glenmark Pharmaceuticals Sa Przeciwciała przeciwko integrynie alfa2 i ich zastosowania
CN101294198A (zh) * 2007-04-27 2008-10-29 上海人类基因组研究中心 冠心病检测方法和试剂盒
WO2009100110A1 (fr) * 2008-02-05 2009-08-13 Medarex, Inc. Anticorps alpha 5-bêta 1 et leurs utilisations
JP5775458B2 (ja) * 2008-11-06 2015-09-09 グレンマーク ファーマシューティカルズ, エセ.アー. 抗α2インテグリン抗体を使用する処置
RU2545401C2 (ru) * 2010-02-23 2015-03-27 Санофи Антитела к интегрину альфа-2 и их применения
TWI560199B (en) * 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same

Also Published As

Publication number Publication date
JOP20240284A1 (ar) 2024-12-22
JP2025524306A (ja) 2025-07-29
EP4545563A1 (fr) 2025-04-30
CL2024004023A1 (es) 2025-07-25
KR20250042144A (ko) 2025-03-26
WO2024001669A1 (fr) 2024-01-04
CA3259463A1 (fr) 2025-04-18
IL317725A (en) 2025-02-01
CN119343378A (zh) 2025-01-21
MX2024016011A (es) 2025-04-02
WO2024001669A9 (fr) 2024-11-14
CO2025000762A2 (es) 2025-04-16
AU2023301621A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
EP3941945A4 (fr) Anticorps dirigés contre l'antigène trophoblaste 2 de surface cellulaire (trop2) et conjugués anticorps-médicament les comprenant
EP3877416A4 (fr) Anticorps anti-cd45 et leurs conjugués
EP3941946A4 (fr) Anticorps anti-claudine-6 et conjugués de médicaments
IL290979A (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
EP3936501C0 (fr) Conjugaison d'anticorps spécifique à un site et conjugué anticorps-médicament servant d'exemple spécifique de celui-ci
EP4161582A4 (fr) Conjugués anticorps-médicament contenant un anticorps anti-mésothéline et leurs utilisations
IL299362A (en) Antibody-drug conjugates that include anti-H3-B7 antibodies
EP3638697A4 (fr) Anticorps anti-il1rap et conjugués anticorps-médicament
IL300176A (en) Anti-cd228 antibodies and antibody-drug conjugates
KR20240001074A9 (ko) 하나의 항체에 2종의 약물-링커 접합체가 연결된 항체-약물 접합체
EP4043034A4 (fr) Conjugué anticorps-médicament de ciblage de lysosome et utilisation correspondante
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP4247425A4 (fr) Anticorps modifié, conjugué anticorps-médicament et son utilisation
IL284673A (en) Traceless linkers and protein-conjugates thereof
EP4279505A4 (fr) Anticorps monoclonal ciblant le cd276 humain et son application
EP4323009A4 (fr) Lieurs, conjugués et leurs applications
MA49987A (fr) Préparation de conjugué anticorps-médicament et lyophilisation associée
EP3735271A4 (fr) Anticorps anti-facteur tissulaire, conjugués anticorps-médicament et procédés associés
IL284974A (en) Anti-cd228 antibodies and antibody-drug conjugates
MA49273A (fr) Anticorps anti-tmeff1 et conjugués anticorps-médicament
EP4188449A4 (fr) Conjugués anticorps-médicament anti-tm4sf1 comprenant des lieurs clivables et leurs méthodes d'utilisation
EP3995496A4 (fr) Médicament de camptothécine et un conjugué d'anticorps de celui-ci
EP4458850A4 (fr) Anticorps anti-ror1, conjugué anticorps anti-ror1-médicament et leurs utilisations médicales
EP4335873A4 (fr) Anticorps anti-claudine 18.2 et conjugué anticorps-médicament de celui-ci
EP4188544A4 (fr) Formulations d'anticorps anti-connexine